Tziporah Kay
Physician Assistant · Brooklyn, NYNPI 1225674393
Payments from drug & device makers
Across 668 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- Acadia Pharmaceuticals Inc$1K
- Amneal Pharmaceuticals LLC$1K
- MDD US Operations, LLC$964
- plus $6K from 36 others
What the payments were for
- Speaking & faculty fees$1361%
- Travel & lodging$1,84912%
- Food & beverage$12,46284%
- Education$4583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,905 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 392 | $476,903 |
| NuplazidPimavanserin Tartrate | 40 | $278,377 |
| NeuproRotigotine | 82 | $123,509 |
| IngrezzaValbenazine Tosylate | 13 | $122,573 |
| Rivastigmine | 370 | $77,759 |
| OngentysOpicapone | 46 | $64,699 |
| Rasagiline Mesylate | 237 | $55,768 |
| BriviactBrivaracetam | 20 | $53,139 |
| NourianzIstradefylline | 12 | $45,719 |
| Emgality PenGalcanezumab-Gnlm | 41 | $41,476 |
| AptiomEslicarbazepine Acetate | 13 | $31,361 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 93 | $24,638 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $21,945 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 317 | $20,910 |
| Selegiline Hcl | 211 | $15,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $1,033 | $476,903392 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,247 | $278,37740 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $570 | $187,27259 claims |
| UCB, Inc.Neupro, Briviact | $644 | $176,648102 claims |
| Kyowa Kirin, Inc.Nourianz | $46 | $45,71912 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $106 | $31,36113 claims |
| Lilly USA, LLCCymbalta | $257 | $6,68413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Melissa VelezBrooklyn$68K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.